Iradimed (IRMD) Cash & Equivalents (2013 - 2026)

Iradimed (IRMD) has 14 years of Cash & Equivalents data on file, last reported at $56.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 12.01% year-over-year to $56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (up 12.01% YoY) and the FY2025 annual result came in at $51.2 million, down 2.06% from the prior year.
• Cash & Equivalents improved to $56.4 million in Q1 2026 per IRMD's latest filing, from $51.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $58.0 million in Q4 2022 and bottomed at $42.8 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $51.2 million (2025), against an average of $51.0 million.
• The widest annual swing landed in 2023, when Cash & Equivalents decreased 15.91%; it then grew 12.01% in 2026.
• Tracing IRMD's Cash & Equivalents over 5 years: stood at $58.0 million in 2022, then slipped by 14.15% to $49.8 million in 2023, then climbed by 4.97% to $52.2 million in 2024, then decreased by 2.06% to $51.2 million in 2025, then gained by 10.19% to $56.4 million in 2026.
• Per Business Quant, the three latest IRMD Cash & Equivalents figures stand at $56.4 million (Q1 2026), $51.2 million (Q4 2025), and $56.5 million (Q3 2025).

Peer Comparison